Müller-Gärtner H W, Erttmann R, Helmke K
Department of Nuclear Medicine, University of Hamburg, F.R.G.
Pediatr Hematol Oncol. 1986;3(2):97-109. doi: 10.3109/08880018609031205.
To evaluate the accuracy of meta-iodobenzylguanidine (MIBG) imaging in comparison with bone X-ray and ultrasound, 15 patients with histologically verified neuroblastoma were investigated using 123- or 131MIBG scintigraphy. 123MIBG and 131MIBG are used as the abbreviations for 123-iodine-labeled-MIBG and 131-iodine-labeled-MIBG, respectively. Either 7.4 MBq 131MIBG (n = 4) or 111-185 MBq 123MIBG (n = 11) was applied, and scans were performed 24 and 48 h PI. Anatomical orientation was provided in selected cases by single-photon emission CT or scintigraphy of other organs. X-ray procedures or ultrasound depicted 27 neuroblastoma manifestations (primary tumors and metastatic deposits); 24 of these (89%) were identified by MIBG scintigraphy. Of 42 primary neuroblastomas and metastatic deposits, 27 (64%) were detected by corresponding bone X-ray or ultrasound. The 15 neuroblastoma lesions depicted solely by MIBG scans were mainly (80%) situated in the skeletal system. Because of the pronounced physiological MIBG uptake by liver tissue, detection of intrahepatic or perihepatic tumor involvement is difficult. MIBG scintigraphy is a safe and noninvasive means of locating a wide range of neuroblastoma lesions. Its main diagnostic advantage in comparison with bone X-ray lies in the detection of bone marrow infiltration.
为了评估间碘苄胍（MIBG）成像相对于骨X线和超声检查的准确性，我们使用123I或131I-MIBG闪烁扫描对15例经组织学证实的神经母细胞瘤患者进行了研究。123MIBG和131MIBG分别用作123碘标记的MIBG和131碘标记的MIBG的缩写。应用了7.4 MBq的131MIBG（n = 4）或111 - 185 MBq的123MIBG（n = 11），并在注射后24小时和48小时进行扫描。在选定的病例中，通过单光子发射CT或其他器官的闪烁扫描提供解剖定位。X线检查或超声检查发现了27处神经母细胞瘤表现（原发肿瘤和转移灶）；其中24处（89%）通过MIBG闪烁扫描得以识别。在42处原发性神经母细胞瘤和转移灶中，27处（64%）通过相应的骨X线或超声检查被检测到。仅通过MIBG扫描发现的15处神经母细胞瘤病灶主要（80%）位于骨骼系统。由于肝组织对MIBG有明显的生理性摄取，因此难以检测肝内或肝周肿瘤受累情况。MIBG闪烁扫描是一种安全、无创的方法，可用于定位多种神经母细胞瘤病灶。与骨X线相比，其主要诊断优势在于能够检测骨髓浸润。
